Table 1.
Characteristics of patients with advanced PC.
| Characteristics | No. of Patients (n = 98) | Percentage (%) |
|---|---|---|
| Age, years | ||
| ≥60 | 32 | 32.7 |
| <60 | 66 | 67.3 |
| Sex | ||
| Male | 70 | 71.4 |
| Female | 28 | 28.6 |
| PD-1 inhibition agent | ||
| Nivolumab | 33 | 33.7 |
| Pembrolizumab | 9 | 9.2 |
| Sintilimab | 56 | 57.1 |
| Smoking history | ||
| Smoke | 36 | 36.7 |
| Never smoke | 62 | 63.3 |
| Smoking exposure, pack-years | ||
| ≤30 | 83 | 84.7 |
| >30 | 15 | 15.3 |
| Histological differentiating degree | ||
| Low differentiation | 56 | 57.1 |
| Moderate and high differentiation | 42 | 42.9 |
| Metastatic sites | ||
| 0–2 | 84 | 85.7 |
| >2 | 14 | 14.3 |
| Baseline CA19-9 | ||
| ≤ULN | 23 | 23.5 |
| >ULN | 68 | 69.4 |
| Missing | 7 | 7.1 |
| Prior target therapy | ||
| Yes | 8 | 8.2 |
| No | 86 | 87.8 |
| Missing | 4 | 4.1 |
| Combined with other drugs | ||
| Yes | 91 | 92.9 |
| No | 7 | 7.1 |
| Line of immunotherapy | ||
| 1st | 75 | 76.5 |
| 2nd | 16 | 16.3 |
| 3rd or above | 7 | 7.1 |
| LDH | ||
| ≥ULN | 7 | 7.1 |
| <ULN | 91 | 92.9 |
| dNLR | ||
| ≥3 | 34 | 34.7 |
| <3 | 64 | 65.3 |
| dNLR-LDH indicator | ||
| Good | 61 | 62.2 |
| Intermediate/poor | 37 | 37.8 |
PD-1, programmed cell death-1; LDH, lactate dehydrogenase; ULN, upper limit of normal; dNLR, derived neutrophil-to-lymphocyte ratio.